The Dutch Healthcare Institute (ZIN) published the Position on Flash Glucose Monitoring (FGM) for people with diabetes with an intensive insulin schedule in 2019. In this position, the ZIN concluded that FGM as a medical aid must be reimbursed under the basic insurance package for people with type 1 and type 2 diabetes with an intensive insulin schedule.
Currently, the following questions are considered under the ZIN evaluation:
- Have the quality criteria for appropriate use of the FGM been worked out before the end of the second quarter of 2020? Have the quality criteria of the FGM and rt-CGM been adjusted?
- What are the developments in costs, volume, and the number of patients eligible for FGM (reader and sensor)? Is it in line with the estimate of the position?
- What are the developments in costs, volume, and the number of patients eligible for rt-CGM? Is it in line with the estimate of the position?
- What are the developments in costs, volume, and the number of patients eligible for test strips? Is it in line with the estimate of the position?
- Will the selling price of the FGM decrease as its use increases?
- Is compliance with the quality criteria ensured, and how is it done?
The publication of the results of the first interim assessment is scheduled for the fourth quarter of 2021.
The full details in Dutch can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).